Related Experiment Video
Updated: Oct 25, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Overview of Cardiomyopathies in Childhood
Anika Rath1, Robert Weintraub1,2,3
1Department of Cardiology, Royal Children's Hospital, Melbourne, VIC, Australia.
Insights
Childhood cardiomyopathies, rare heart muscle disorders, affect 1 in 100,000 children. Survival rates vary by type, with most adverse events occurring within two years of diagnosis.
Area of Science:
- Pediatric Cardiology
- Rare Diseases
- Cardiovascular Research
Background:
- Paediatric cardiomyopathies are rare, heterogeneous heart muscle disorders affecting children.
- Incidence is approximately 1 per 100,000, with higher rates in the first two years of life.
- Dilated cardiomyopathy is most common, followed by hypertrophic, left ventricular non-compaction, and restrictive types.
Purpose of the Study:
- To provide an overview of childhood cardiomyopathies.
- Focus on epidemiology, natural history, and outcomes.
- Highlighting survival rates and adverse event timelines.
Main Methods:
- Review of a national population-based study.
- Analysis of epidemiological data.
- Examination of natural history and long-term outcomes.
Main Results:
- 10-year transplant-free survival rates: Hypertrophic (80%), Dilated (62%), Left Ventricular Non-Compaction (48%).
- Restrictive cardiomyopathy outcomes often obscured by early heart transplantation.
- Most adverse events, including death and transplantation, occur within two years of presentation.
Conclusions:
- Childhood cardiomyopathies have variable natural histories and outcomes influenced by type and cause.
- Early identification and management are crucial, especially within the first two years.
- Further research needed for restrictive phenotypes and long-term survival.
Abstract:
Paediatric cardiomyopathies are a heterogenous group of rare disorders, characterised by mechanical and electrical abnormalities of the heart muscle. The overall annual incidence of childhood cardiomyopathies is estimated at about 1 per 100,000 children and is significantly higher during the first 2 years of life. Dilated cardiomyopathies account for approximately half of the cases. Hypertrophic cardiomyopathies form the second largest group, followed by the less common left ventricular non-compaction and restrictive phenotypes. Infectious, metabolic, genetic, and syndromic conditions account for the majority of cases. Congestive heart failure is the typical manifestation in children with dilated cardiomyopathy, whereas presenting symptoms are more variable in other phenotypes. The natural history is largely influenced by the type of cardiomyopathy and its underlying aetiology. Results from a national population-based study revealed 10-year transplant-free survival rates of 80, 62, and 48% for hypertrophic, dilated and left ventricular non-compaction cardiomyopathies, respectively. Long-term survival rates of children with a restrictive phenotype have largely been obscured by early listing for heart transplantation. In general, the majority of adverse events, including death and heart transplantation, occur during the first 2 years after the initial presentation. This review provides an overview of childhood cardiomyopathies with a focus on epidemiology, natural history, and outcomes.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Myocarditis I: Introduction

